other material
confidence high
sentiment positive
materiality 0.85
Corbus CANYON-1: CRB-913 hits 5% mean weight loss at 60 mg; all doses p<0.0001
Corbus Pharmaceuticals Holdings, Inc.
- Phase 1b CANYON-1 (NCT07310901): 254 obese adults, 16-week trial; LS mean weight loss vs placebo: 2.8% (20 mg), 3.3% (40 mg), 5.0% (60 mg) at week 12, all p<0.0001.
- Safety: no serious psychiatric AEs, no suicidality; GI AEs milder than oral GLP-1s (vomiting 1.6-8.2% vs 31% for semaglutide 25 mg).
- Discontinuation rate due to AEs 3.1%-13.1%, markedly lower than monlunabant's 13%-42%.
- Data selected for late-breaking presentation at ObesityWeek 2026 (Nov 14-17, 2026).
- Plans FDA engagement and Phase 2 monotherapy start in 1H 2027; evaluating combo with GLP-1 therapy.